Repligen traded at $117.78 this Thursday April 2nd, decreasing $0.54 or 0.46 percent since the previous trading session. Looking back, over the last four weeks, Repligen lost 4.29 percent. Over the last 12 months, its price fell by 3.22 percent. Looking ahead, we forecast Repligen to be priced at 114.23 by the end of this quarter and at 104.23 in one year, according to Trading Economics global macro models projections and analysts expectations.
Repligen Corporation is a life sciences company that develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, Filtration; Chromatography; Process Analytics; and Proteins. The Filtration products are used in process development and process scale (clinical and commercial) production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market.